Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CPRX – Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.
CPRX
$21.12
Name : Catalyst Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,576,112,128.00
EPSttm : 1.57
finviz dynamic chart for CPRX
Catalyst Pharmaceuticals, Inc.
$21.12
0.98%
$0.21

Float Short %

8.02

Margin Of Safety %

49

Put/Call OI Ratio

0.95

EPS Next Q Diff

0.07

EPS Last/This Y

0.72

EPS This/Next Y

0.25

Price

21.12

Target Price

34.29

Analyst Recom

1.14

Performance Q

-12.98

Relative Volume

0.79

Beta

0.7

Ticker: CPRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04CPRX21.461.320.757956
2025-07-07CPRX20.941.300.607942
2025-07-08CPRX20.751.290.028032
2025-07-09CPRX21.621.230.088192
2025-07-10CPRX21.841.200.038286
2025-07-11CPRX21.811.170.048407
2025-07-14CPRX21.631.120.028607
2025-07-15CPRX20.941.090.088724
2025-07-16CPRX21.181.070.378807
2025-07-17CPRX21.470.980.238500
2025-07-18CPRX21.040.890.368295
2025-07-21CPRX211.090.147181
2025-07-22CPRX20.921.061.927280
2025-07-23CPRX21.571.170.077909
2025-07-24CPRX21.021.080.118260
2025-07-25CPRX20.981.040.158431
2025-07-28CPRX20.811.010.548540
2025-07-29CPRX21.020.990.048624
2025-07-30CPRX21.270.960.058804
2025-07-31CPRX21.330.970.168750
2025-08-01CPRX21.120.950.258887
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04CPRX21.46-3.3-10.82.10
2025-07-07CPRX20.96-3.3-17.52.10
2025-07-08CPRX20.75-3.3-13.62.10
2025-07-09CPRX21.62-3.31.12.10
2025-07-10CPRX21.85-3.3-8.02.10
2025-07-11CPRX21.81-3.3-8.42.10
2025-07-14CPRX21.63-3.3-13.22.10
2025-07-15CPRX20.95-3.3-19.62.10
2025-07-16CPRX21.18-3.3-7.72.10
2025-07-17CPRX21.45-3.3-7.22.10
2025-07-18CPRX21.04-3.3-16.32.10
2025-07-21CPRX21.01-3.3-11.12.10
2025-07-22CPRX20.89-3.3-12.52.10
2025-07-23CPRX21.57-3.3-1.72.10
2025-07-24CPRX21.02-3.3-18.02.10
2025-07-25CPRX20.97-3.3-11.62.10
2025-07-28CPRX20.81-3.3-13.12.10
2025-07-29CPRX21.01-2.9-7.92.10
2025-07-30CPRX21.28-2.9-7.42.10
2025-07-31CPRX21.33-2.9-10.22.10
2025-08-01CPRX21.12-2.9-13.62.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04CPRX-6.591.166.96
2025-07-07CPRX-6.591.166.96
2025-07-08CPRX-6.591.166.96
2025-07-09CPRX-6.591.166.96
2025-07-10CPRX-6.591.166.96
2025-07-11CPRX-6.591.167.35
2025-07-14CPRX-6.591.327.35
2025-07-15CPRX-6.591.327.35
2025-07-16CPRX-6.591.327.35
2025-07-17CPRX-6.591.327.35
2025-07-18CPRX-6.591.327.35
2025-07-21CPRX-6.590.597.35
2025-07-22CPRX-6.590.597.35
2025-07-23CPRX-6.590.597.35
2025-07-24CPRX-6.590.597.35
2025-07-25CPRX-6.590.598.02
2025-07-28CPRX-6.590.308.02
2025-07-29CPRX-6.620.308.02
2025-07-30CPRX-6.620.308.02
2025-07-31CPRX-6.620.308.02
2025-08-01CPRX-6.620.308.02
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.45

Avg. EPS Est. Current Quarter

0.54

Avg. EPS Est. Next Quarter

0.52

Insider Transactions

-6.62

Institutional Transactions

0.3

Beta

0.7

Average Sales Estimate Current Quarter

139

Average Sales Estimate Next Quarter

138

Fair Value

31.42

Quality Score

93

Growth Score

100

Sentiment Score

73

Actual DrawDown %

20.5

Max Drawdown 5-Year %

-45.4

Target Price

34.29

P/E

13.48

Forward P/E

11.99

PEG

1.1

P/S

4.82

P/B

3.24

P/Free Cash Flow

9.63

EPS

1.57

Average EPS Est. Cur. Y​

2.1

EPS Next Y. (Est.)

2.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

36.91

Relative Volume

0.79

Return on Equity vs Sector %

1.1

Return on Equity vs Industry %

19.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-13.6
Catalyst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading